Lilly rises after Novo reports CagriSema beats 5mg tirzepatide
Novo Nordisk said CagriSema beat tirzepatide’s 5-milligram dose in a late-stage diabetes study. Lilly shares still climbed about 1.2% to $1,166.74.
Eli Lilly NYSE:LLY, the obesity-and-diabetes medicine leader, faced a fresh competitive data point Monday after Novo Nordisk NYSE:NVO said CagriSema beat tirzepatide's 5-milligram dose in a late-stage diabetes study. 74, suggesting investors were not…